Please login to the form below

Not currently logged in
Email:
Password:

Aeras

This page shows the latest Aeras news and features for those working in and with pharma, biotech and healthcare.

Tuberculosis: treatment and prevention

Tuberculosis: treatment and prevention

Aeras and GlaxoSmithKline (GSK) Biologicals have entered into a public-private partnership to develop GSK's tuberculosis vaccine candidate, GSK 692342. ... incentives. The Bill and Melinda Gates Foundation recently gifted $280m to the Aeras Global TB

Latest news

  • GSK boost vaccines capabilities with €250m Okairos purchase GSK boost vaccines capabilities with €250m Okairos purchase

    Okairos, which has received investment from BioMedInvest, Boehringer Ingelheim, LSP, Novartis and Versant Ventures, has already received attention for its novel chimpanzee-based platform, including a collaboration with Aeras and the

  • TB vaccine disappoints, but others in the pipeline TB vaccine disappoints, but others in the pipeline

    Helen McShane of the University of Oxford in the UK. The trial was sponsored by non-profit vaccines company Aeras, the Wellcome Trust and the Oxford-Emergent Tuberculosis Consortium (OETC), a ... Meanwhile, there are several other TB vaccines in the

  • Dutch invest in TB vaccines

    The funding has also made a valuable contribution to Crucell and Aeras' AdVac-based TB vaccine. ... of limited investment - which Aeras TB Global president and CEO, Dr Jerald Sadoff, hopes will be further remedied by the recent Dutch input.

  • Tackling the TB threat

    Among these is a recombinant adenoviral vector TB vaccine, currently in phase I trials, being developed by Crucell and Aeras Global TB Vaccine Foundation, an international non-profit academia-industry partnership. ... Further along the pipeline, in phase

More from news
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Interview: Charles Mgone, EDCTP Interview: Charles Mgone, EDCTP

    But it doesn't stop the contagious form acquired by adults. So we are working with Emergent BioSolutions and Aeras, a non-profit product developer, as well as institutions in the

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics